Sanofi: Bryan Garnier adjusts target price.
(CercleFinance.com) - While maintaining its "neutral" rating on Sanofi, Bryan Garnier has adjustd its fair value from 91.
5 euros to 90 euros, despite "what was a rather good quarter at first glance" for the health group.
"Underlying trends were not so good since Q2 numbers included some one-offs whereas new competition is emerging for old profitable drugs like Renagel and Lovenox," analysts say.
"In the end, we are left with pretty limited core EPS growth prospects for this year and next with too much dependency on Dupixent to grow," the broker continues.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
5 euros to 90 euros, despite "what was a rather good quarter at first glance" for the health group.
"Underlying trends were not so good since Q2 numbers included some one-offs whereas new competition is emerging for old profitable drugs like Renagel and Lovenox," analysts say.
"In the end, we are left with pretty limited core EPS growth prospects for this year and next with too much dependency on Dupixent to grow," the broker continues.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.